BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  Merck’s Busy Day: FDA Rejection, EU Recommendation and a Spinoff Sale

  Merck is having a very busy week. Here’s today’s news.

  March 30, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  TCR2 Therapeutics Leases Manufacturing Space in Maryland, Autolus Backs Out of U.S. Expansion

  After Autolus Therapeutics’ backed out of its plan to establish a manufacturing center in Rockville, Maryland, Massachusetts-based TCR2 Therapeutics has stepped up to the plate to build an 85,000 square-foot cell therapy manufacturing facility in Rockville.

  March 30, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  ALS Patients Fight for the Right to Try and Patient-Centric Trial Design

  Lisa Stockman Mauriello was diagnosed with ALS in January and is seeking access to Biogen’s tofersen (BIIB067) through the Right to Try Act. Her case has reinvigorated the ALS community and its fight for expanded access to investigational therapies for this cruel, always fatal disease.

  March 30, 2021

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Business

  Takeda Pairs Up With BridGene to Solve “Undruggable” Neurodegenerative Diseases

  The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.

  March 30, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Global Vaccine Passports Edge Closer, Speeding Arrival of the Next “Normal”

  Vaccine passports are an interim step that can speed the return of some semblance of normality by allowing the rapidly growing numbers of vaccinated people to travel more easily and to attend typically crowded sporting events, concerts and religious services.

  March 30, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Merck KGaA’s ATR Inhibitor Shows Promise in Both Cancer and COVID-19

  A research collaboration among UCLA investigators and Merck KGaA, has pointed to the drug as showing promise for COVID-19. It is also being touted for its unusually broad effect in treating a range of cancers.

  March 30, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie Receives NDA for Atogepant, Aims to Stop Migraines in Their Tracks

  AbbVie won the NDA on the strength of definitive results in a Phase III ADVANCE trial, where atogepant met all six secondary endpoints at the 30-60 mg dose range, proving statistically significant in heading off migraines in nearly 2500 adult participants who experience them between 4-14 days per month.

  March 30, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Genetown

  Omega Raises $126 Million to Unlock Potential of Epigenomic Controller Candidate

  Omega Therapeutics secured $126 million in a Series C financing round that will be used to advance the company’s lead epigenomic controller candidate, OTX-2002, a potential treatment for hepatocellular carcinoma, as well as other next-generation pipeline assets.

  March 30, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Bionic Sight’s Optogenetic Therapy Yields Bright Results

  The first four patients that were administered BS01, Bionic Sight’s investigational gene therapy for advanced retinitis pigmentosa (RP), all reported the ability to detect light and motion. Two of the patients were also able to detect direction.

  March 30, 2021

   · 

  2 min read

   · 

  Kristiane Polido
• 

  Business

  Money on the Move: March 24-30

  Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.

  March 30, 2021

   · 

  5 min read

   · 

  Kate Goodwin